Navigating second-line therapy after immunotherapy in advanced HCC☆.

JHEP Rep · 2026 · PMC12769797 · PMID 41503573

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While lenvatinib was associated with slightly longer median OS (12.42 months) and median PFS (5.15 months) compared to sorafenib (10.75 and 2.58 months, respectively), the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.